News

Nasdaq11mon
Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma
is pleased to announce that it received a No Objection Letter ("NOL") from Health Canada for its Clinical Trial Study number ACCUM-002-01 entitles "A Phase I trial of Intratumoral Administration ...
Business Line7mon
IRDAI’s no-objection letter not a final regulatory nod for Burman family’s open offer, Religare Enterprises clarifies
Therefore, the letter from IRDAI is a “mere no objection” and not an approval ... that “the open offer …does not involve any transfer of shares of CHIL. Accordingly, the provisions ...
Nasdaq3mon
Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute ...
titled “Prevention Of NephroToxin Induced Acute Kidney Injury with Cilastatin” (PONTiAK), has received a No Objection Letter (NOL) from Health Canada to proceed with the trial. PONTiAK is a ...